Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

I'm Anne Kramer. I'm a postdoctoral fellow at Stanford University and I've been studying a new CAR-T as a therapy for patients with large piece of lymphoma. CAR-T cell therapy has really transformed the way we treat patients with lymphoma and it can achieve durable responses, meaning that patients get cured of their disease with potential that of the disease never recurring. However, unfortunately for about half of the patients we do see progression after receiving CAR-19 therapy and for those patients historically it's been very difficult to treat them further with very limited responses to further lines of therapy and relatively short overall survival after these patients progressed to CAR-19. So given this unmet need at Stanford we have investigated a new CAR which targets a new B-cell marker being CD22 in patients who had relapsed after receiving CAR-19 and in that patient cohort of 38 patients we have found remarkable response rates. So 68% of our patients responded to this therapy of whom 53%, 20 patients achieved a complete remission of their disease and now I've presented data that shows three years out of this therapy, the cohort has been followed up over more than three years now, these responses are actually durable meaning that there's a curative potential of this therapy in these patients which is highly exciting and this was all in the context of a very well tolerated toxicity profile. We know that these therapies can come with side effects and so we're aware of this potential but we saw that with this car it was actually very manageable overall and now long term we also see that the long term side effects are manageable and you know remain under constant evaluation and a follow-up of us but overall we're very excited of this potential new therapy which for which we're now enrolling a phase two trial throughout the whole of U.S. multi-center. You know hopefully replicating the findings that we had in our small 38 patient cohort over a larger number of patients. CAR T cell therapy has really transformed the way we treat patients with lymphoma and it can achieve durable responses meaning that patients get cured of their disease with potential that of the disease never recurring. However unfortunately for about half of the patients we do see progression after receiving current 19 therapy and for those patients historically it's been very difficult to treat them further with very limited responses to further lines of therapy and relatively short overall survival after these patients progressed to car 19. So given this unmet need at Stamford we have investigated a new car which targets a new B cell marker being CD22 in patients who had relapsed after receiving car 19 and in that patient cohort of 38 patients we have found remarkable response rates. So 68 percent of our patients responded to this therapy for of whom 53 percent 20 patients achieved a complete remission of their disease and now I've presented data that shows three years out of this therapy the cohort has been followed up over more than three years now these responses are actually durable meaning that there's a curative potential of this therapy in these patients which is highly exciting and this was all in the context of a very well tolerated toxicity profile. We know that these therapies can come with side effects and so we're aware of of this potential but we saw that with this car it was actually very manageable overall and now long term we also see that the long term side effects are manageable and you know remain under constant evaluation and a follow-up of us but overall we're very excited of this potential new therapy which for which we're now enrolling a phase two trial throughout the whole of US multi-center you know hopefully replicating the findings that we had in our small 38 patient cohort over a larger number of patients. What I do know is that we see improvement of background representation so the population living in our service area so to say is better represented over time now as we enroll more patients on our trials and as we give these therapies to as a commercial therapy so that is improving and we're very aware of that need of you know patients being able to actually get the therapy the ones that deserve it so there's definitely an area of improvement still but we do see you know over time that people are getting better access to these therapies. This therapy now has been so successful that FDA has recognized it and so they made it gave it a breakthrough designation which means that you know should these results be replicated in this larger phase two trial this should expedite you know potential access to this therapy for future patients so that really makes us really exciting and shows the potential of this particular construct.